Washington Trust Advisors Inc. Has $94,000 Stock Position in Stryker Co. (NYSE:SYK)

Washington Trust Advisors Inc. reduced its position in shares of Stryker Co. (NYSE:SYK) by 24.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 315 shares of the medical technology company’s stock after selling 101 shares during the quarter. Washington Trust Advisors Inc.’s holdings in Stryker were worth $94,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in SYK. Vanguard Group Inc. raised its stake in shares of Stryker by 0.5% in the third quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock worth $8,379,967,000 after purchasing an additional 143,631 shares during the last quarter. State Street Corp lifted its stake in Stryker by 2.4% in the 2nd quarter. State Street Corp now owns 14,393,817 shares of the medical technology company’s stock worth $4,402,083,000 after purchasing an additional 340,114 shares in the last quarter. Morgan Stanley lifted its stake in Stryker by 21.7% in the 4th quarter. Morgan Stanley now owns 5,978,782 shares of the medical technology company’s stock worth $1,461,753,000 after purchasing an additional 1,066,751 shares in the last quarter. FMR LLC lifted its stake in Stryker by 2.5% in the 3rd quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock worth $1,632,127,000 after purchasing an additional 144,208 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Stryker by 2.0% in the 1st quarter. Geode Capital Management LLC now owns 5,954,038 shares of the medical technology company’s stock worth $1,695,169,000 after purchasing an additional 117,786 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 212,109 shares of company stock worth $72,845,768. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of several recent analyst reports. Roth Mkm increased their price target on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and increased their target price for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Wells Fargo & Company increased their target price on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Morgan Stanley increased their target price on shares of Stryker from $300.00 to $320.00 and gave the company an “equal weight” rating in a report on Monday, December 4th. Finally, Citigroup increased their price target on shares of Stryker from $340.00 to $362.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $331.52.

Stryker Price Performance

NYSE:SYK traded down $0.80 during trading hours on Thursday, hitting $357.91. 456,654 shares of the stock traded hands, compared to its average volume of 1,313,953. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The company has a market cap of $135.98 billion, a price-to-earnings ratio of 43.15, a price-to-earnings-growth ratio of 2.86 and a beta of 0.89. The stock has a 50 day moving average price of $342.51 and a 200 day moving average price of $305.23.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the previous year, the firm earned $3.00 earnings per share. The company’s quarterly revenue was up 11.8% compared to the same quarter last year. Sell-side analysts forecast that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is presently 38.79%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.